<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02746809</url>
  </required_header>
  <id_info>
    <org_study_id>10211838DOC</org_study_id>
    <nct_id>NCT02746809</nct_id>
  </id_info>
  <brief_title>Medtronic CoreValve Evolut R U.S. Clinical Study (Evolut 34R Addendum)</brief_title>
  <official_title>Medtronic CoreValve Evolut R United States Clinical Study (Evolut 34R Addendum)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Cardiovascular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Cardiovascular</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study objectives are to assess the safety and efficacy of the CoreValve Evolut 34R
      transcatheter aortic valve replacement (TAVR) system in patients with severe symptomatic
      aortic stenosis who are considered at high or extreme risk for surgical aortic valve
      replacement.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This objective will be accomplished by a prospective, single arm, historical controlled,
      multi-site study involving up to 60 implanted subjects at up to 15 study sites in the United
      States. Procedural and 30 day safety and efficacy results from this study will be compared to
      appropriate historical control data for the Medtronic CoreValve System. Subjects will be
      followed up to 5 years following implantation.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With All-cause Mortality</measure>
    <time_frame>30 Days</time_frame>
    <description>Percentage of participants with all-cause mortality at 30 days</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Stroke (Disabling)</measure>
    <time_frame>30 Days</time_frame>
    <description>Percentage of participants with disabling stroke (VARC-II definitions) at 30 days</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Device Success Rate</measure>
    <time_frame>24 hours to 7 days post implantation</time_frame>
    <description>Device Success defined as:
Absence of procedural mortality, AND
Correct positioning of a single prosthetic heart valve into the proper anatomical location, AND
Intended performance of the prosthetic heart valve, defined as the absence of patient prosthesis-mismatch and mean gradient &lt; 20 mmHg (or peak velocity &lt; 3 m/sec), AND
Absence of moderate or severe prosthetic valve regurgitation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Percentage of Subjects With no More Than Mild Prosthetic Regurgitation at Early Post Procedure Echocardiogram</measure>
    <time_frame>24 hours to 7 days post implantation</time_frame>
    <description>The percentage of subjects with no more than mild prosthetic regurgitation at early post procedure echocardiogram as assessed by echo core laboratory</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With VARC II Combined Safety Endpoint Event at 30 Days</measure>
    <time_frame>30 days post-implantation</time_frame>
    <description>VARC II composite safety endpoint includes the following components:
All-cause mortality
All stroke (disabling and non-disabling)
Life-threatening bleeding
Acute kidney injury: stage 2 or 3 (including renal replacement therapy).
Coronary artery obstruction requiring intervention.
Major vascular complication.
Valve-related dysfunction requiring repeat procedure (BAV, TAVR, or SAVR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Life Threatening or Disabling Bleeding</measure>
    <time_frame>30 days post-implantation</time_frame>
    <description>Percentage of participants with life threatening or disabling bleeding - see VARC-2 definitions for classification details</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Major Vascular Complication</measure>
    <time_frame>30 days</time_frame>
    <description>Percentage of participants with Major vascular complication - see VARC-2 definitions for additional details</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Acute Kidney Injury: Stage 2 or 3</measure>
    <time_frame>30 days</time_frame>
    <description>Percentage of participants with Acute Kidney Injury: Stage 2 or 3 - see VARC-2 definitions for additional details</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Coronary Artery Obstruction</measure>
    <time_frame>30 days</time_frame>
    <description>Percentage of participants with coronary artery obstruction - see VARC-2 definitions for additional details</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Valve-related Dysfunction Requiring Repeat Procedure</measure>
    <time_frame>30 days</time_frame>
    <description>Percentage of subjects with valve-related dysfunction requiring repeat procedure - see VARC-2 definitions for additional details</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Permanent Pacemaker Implant at 30 Days</measure>
    <time_frame>30 days</time_frame>
    <description>Percentage of subjects with new permanent pacemaker implant at 30 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Resheath and Recapture Success</measure>
    <time_frame>Implant procedure</time_frame>
    <description>Successful resheathing is defined as Evolut R TAV (including frame) was resheathed into the capsule of the delivery cathether to the desired amount intended, as verified by fluoroscopy.
Successful recapture is defined as the entire Evolut R TAV (including frame) is resheathed into the capsule of the delivery catheter until there is no gap between the capsule and the tip, as verified by fluoroscopy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemodynamic Performance Metrics - Mean Gradient</measure>
    <time_frame>Baseline, 30 days, and 6 months</time_frame>
    <description>Mean gradient (mmHg) as measured by transthoracic echocardiogram and assessed by echo core laboratory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemodynamic Performance Metrics- Aortic Valve Area</measure>
    <time_frame>Baseline, 30 Days, and 6 Months</time_frame>
    <description>Aortic valve area as measured by transthoracic echocardiogram and assessed by echo core laboratory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemodynamic Performance Metrics - Total Prosthetic Regurgitation Graded as None/Trace</measure>
    <time_frame>30 days and 6 months</time_frame>
    <description>Total prosthetic regurgitation (none/trace) as measured by transthoracic echocardiogram and assessed by echo core laboratory</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Aortic Valve Stenosis</condition>
  <arm_group>
    <arm_group_label>CoreValve Evolut 34R TAVR system</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment of Aortic Stenosis with Medtronic CoreValve Evolut R 34R TAVR System.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CoreValve Evolut 34R TAVR system</intervention_name>
    <description>The CoreValve Evolut 34R System is a transcatheter aortic valve implantation system comprised of the following three components:
Evolut 34R Transcatheter Aortic Valve (TAV)
EnVeo R Delivery Catheter System (DCS) with EnVeo R InLine Sheath
EnVeo R Loading System (LS)</description>
    <arm_group_label>CoreValve Evolut 34R TAVR system</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Severe aortic stenosis, defined as aortic valve area of &lt; 1.0 cm2 (or aortic valve
             area index of &lt; 0.6 cm2/m2) by the continuity equation, AND mean gradient &gt; 40 mmHg or
             maximal aortic valve velocity &gt; 4.0 m/sec by resting echocardiogram.

             Subjects with low-flow/low gradient severe aortic stenosis can be included, provided
             low-dose dobutamine or exercise stress echocardiography demonstrates a mean gradient
             of &gt; 40 mmHg or a maximal aortic valve velocity of &gt; 4.0 m/sec, AND aortic valve area
             of &lt; 1.0 cm2 (or aortic valve area index of &lt; 0.6 cm2/m2).

          2. Society of Thoracic Surgeons (STS) score of ≥ 8 OR documented heart team agreement of
             ≥ high risk for aortic valve replacement due to frailty or co-morbidities.

          3. Symptoms of aortic stenosis, AND New York Heart Association (NYHA) Functional Class II
             or greater.

          4. The subject and the treating physician agree that the subject will return for all
             required post-procedure follow-up visits.

             Exclusion Criteria:

          5. Any condition considered a contraindication for placement of a bioprosthetic valve
             (e.g. subject is indicated for mechanical prosthetic valve).

          6. A known hypersensitivity or contraindication to any of the following which cannot be
             adequately pre-medicated:

               -  aspirin or heparin (HIT/HITTS) and bivalirudin

               -  ticlopidine and clopidogrel

               -  Nitinol (titanium or nickel)

               -  contrast media

          7. Blood dyscrasias as defined: leukopenia (WBC &lt; 1000 mm3), thrombocytopenia (platelet
             count &lt;50,000 cells/mm3), history of bleeding diathesis or coagulopathy, or
             hypercoagulable states.

          8. Untreated clinically significant coronary artery disease requiring revascularization.

          9. Severe left ventricular dysfunction with left ventricular ejection fraction (LVEF) &lt;
             20% by echocardiography, contrast ventriculography, or radionuclide ventriculography.

         10. End stage renal disease requiring chronic dialysis or creatinine clearance &lt; 20
             cc/min.

         11. Ongoing sepsis, including active endocarditis.

         12. Any percutaneous coronary or peripheral interventional procedure with a bare metal or
             drug eluting stent performed within 30 days prior to study procedure.

         13. Symptomatic carotid or vertebral artery disease or successful treatment of carotid
             stenosis within 10 weeks of Heart Team assessment.

         14. Cardiogenic shock manifested by low cardiac output, vasopressor dependence, or
             mechanical hemodynamic support.

         15. Recent (within 6 months of Heart Team assessment) cerebrovascular accident (CVA) or
             transient ischemic attack (TIA).

         16. Gastrointestinal (GI) bleeding that would preclude anticoagulation.

         17. Subject refuses a blood transfusion.

         18. Severe dementia (resulting in either inability to provide informed consent for the
             study/procedure, prevents independent lifestyle outside of a chronic care facility, or
             will fundamentally complicate rehabilitation from the procedure or compliance with
             follow-up visits).

         19. Estimated life expectancy of less than 12 months due to associated non-cardiac
             co-morbid conditions.

         20. Other medical, social, or psychological conditions that in the opinion of the
             investigator precludes the subject from appropriate consent or adherence to the
             protocol required follow-ups exams.

         21. Currently participating in an investigational drug or another device study (excluding
             registries).

         22. Evidence of an acute myocardial infarction ≤ 30 days before the study procedure.

         23. Need for emergency surgery for any reason.

         24. Liver failure (Child-Pugh class C).

         25. Subject is pregnant or breast feeding.

             Anatomical exclusion criteria:

         26. Pre-existing prosthetic heart valve in any position.

         27. Mixed aortic valve disease (aortic stenosis with severe aortic regurgitation).

         28. Severe mitral regurgitation.

         29. Severe tricuspid regurgitation.

         30. Moderate or severe mitral stenosis.

         31. Hypertrophic obstructive cardiomyopathy.

         32. Echocardiographic or Multi-Slice Computed Tomography (MSCT) evidence of intracardiac
             mass, thrombus, or vegetation.

         33. Congenital bicuspid or unicuspid valve verified by echocardiography.

             For transfemoral or transaxillary (subclavian) access:

         34. Access vessel diameter &lt; 5.5 mm or &lt;6.0 mm for patent left internal mammary artery
             (LIMA)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mathew R Williams, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU Langone Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jeffrey J Popma, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beth Israel Deaconess Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yale New Haven Hospital</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Health Systems</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spectrum Health Hospitals</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Langone Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Francis Hospital</name>
      <address>
        <city>Roslyn</city>
        <state>New York</state>
        <zip>11576</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riverside Methodist Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pinnacle Health/Moffitt Heart and Vascular Institute</name>
      <address>
        <city>Harrisburg</city>
        <state>Pennsylvania</state>
        <zip>17104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor Heart and Vascular Hospital</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aurora Health Care/St Luke's Medical Center</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 18, 2016</study_first_submitted>
  <study_first_submitted_qc>April 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2016</study_first_posted>
  <results_first_submitted>November 28, 2017</results_first_submitted>
  <results_first_submitted_qc>November 28, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">December 29, 2017</results_first_posted>
  <last_update_submitted>April 26, 2018</last_update_submitted>
  <last_update_submitted_qc>April 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>CoreValve Evolut R TAVR System 34R Valve</title>
          <description>The CoreValve Evolut 34R System is a transcatheter aortic valve implantation system comprised of the following three components:
Evolut 34R Transcatheter Aortic Valve (TAV)
&gt;
EnVeo R 20Fr Delivery Catheter System (DCS) with EnVeo R InLine Sheath
&gt;
EnVeo R Loading System (LS)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Baseline- 30 Days</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Baseline-6 Months</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CoreValve Evolut 34R TAVR System</title>
          <description>Treatment of Aortic Stenosis with Medtronic CoreValve Evolut R 34R TAVR System. &gt;
&gt; CoreValve Evolut 34R TAVR system: The CoreValve Evolut 34R System is a transcatheter aortic valve implantation system comprised of the following three components: &gt;
Evolut 34R Transcatheter Aortic Valve (TAV) &gt;
EnVeo R Delivery Catheter System (DCS) with EnVeo R InLine Sheath &gt;
EnVeo R Loading System (LS)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="81.8" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With All-cause Mortality</title>
        <description>Percentage of participants with all-cause mortality at 30 days</description>
        <time_frame>30 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CoreValve Evolut 34R TAVR System</title>
            <description>Treatment of Aortic Stenosis with Medtronic CoreValve Evolut R 34R TAVR System.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With All-cause Mortality</title>
          <description>Percentage of participants with all-cause mortality at 30 days</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" lower_limit="0.2" upper_limit="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Stroke (Disabling)</title>
        <description>Percentage of participants with disabling stroke (VARC-II definitions) at 30 days</description>
        <time_frame>30 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CoreValve Evolut 34R TAVR System</title>
            <description>Treatment of Aortic Stenosis with Medtronic CoreValve Evolut R 34R TAVR System.
CoreValve Evolut 34R TAVR system: The CoreValve Evolut 34R System is a transcatheter aortic valve implantation system comprised of the following three components:
Evolut 34R Transcatheter Aortic Valve (TAV)
EnVeo R Delivery Catheter System (DCS) with EnVeo R InLine Sheath
EnVeo R Loading System (LS)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Stroke (Disabling)</title>
          <description>Percentage of participants with disabling stroke (VARC-II definitions) at 30 days</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Device Success Rate</title>
        <description>Device Success defined as:
Absence of procedural mortality, AND
Correct positioning of a single prosthetic heart valve into the proper anatomical location, AND
Intended performance of the prosthetic heart valve, defined as the absence of patient prosthesis-mismatch and mean gradient &lt; 20 mmHg (or peak velocity &lt; 3 m/sec), AND
Absence of moderate or severe prosthetic valve regurgitation</description>
        <time_frame>24 hours to 7 days post implantation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CoreValve Evolut 34R TAVR System</title>
            <description>Treatment of Aortic Stenosis with Medtronic CoreValve Evolut R 34R TAVR System.
&gt;
&gt;
CoreValve Evolut 34R TAVR system: The CoreValve Evolut 34R System is a transcatheter aortic valve implantation system comprised of the following three components:
Evolut 34R Transcatheter Aortic Valve (TAV)
&gt;
EnVeo R Delivery Catheter System (DCS) with EnVeo R InLine Sheath
&gt;
EnVeo R Loading System (LS)</description>
          </group>
        </group_list>
        <measure>
          <title>Device Success Rate</title>
          <description>Device Success defined as:
Absence of procedural mortality, AND
Correct positioning of a single prosthetic heart valve into the proper anatomical location, AND
Intended performance of the prosthetic heart valve, defined as the absence of patient prosthesis-mismatch and mean gradient &lt; 20 mmHg (or peak velocity &lt; 3 m/sec), AND
Absence of moderate or severe prosthetic valve regurgitation</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.2" lower_limit="65.9" upper_limit="89.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Percentage of Subjects With no More Than Mild Prosthetic Regurgitation at Early Post Procedure Echocardiogram</title>
        <description>The percentage of subjects with no more than mild prosthetic regurgitation at early post procedure echocardiogram as assessed by echo core laboratory</description>
        <time_frame>24 hours to 7 days post implantation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CoreValve Evolut 34R TAVR System</title>
            <description>Treatment of Aortic Stenosis with Medtronic CoreValve Evolut R 34R TAVR System.
&gt;
&gt;
CoreValve Evolut 34R TAVR system: The CoreValve Evolut 34R System is a transcatheter aortic valve implantation system comprised of the following three components:
Evolut 34R Transcatheter Aortic Valve (TAV)
&gt;
EnVeo R Delivery Catheter System (DCS) with EnVeo R InLine Sheath
&gt;
EnVeo R Loading System (LS)</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of Subjects With no More Than Mild Prosthetic Regurgitation at Early Post Procedure Echocardiogram</title>
          <description>The percentage of subjects with no more than mild prosthetic regurgitation at early post procedure echocardiogram as assessed by echo core laboratory</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="93.9" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With VARC II Combined Safety Endpoint Event at 30 Days</title>
        <description>VARC II composite safety endpoint includes the following components:
All-cause mortality
All stroke (disabling and non-disabling)
Life-threatening bleeding
Acute kidney injury: stage 2 or 3 (including renal replacement therapy).
Coronary artery obstruction requiring intervention.
Major vascular complication.
Valve-related dysfunction requiring repeat procedure (BAV, TAVR, or SAVR)</description>
        <time_frame>30 days post-implantation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CoreValve Evolut 34R TAVR System</title>
            <description>Treatment of Aortic Stenosis with Medtronic CoreValve Evolut R 34R TAVR System.
&gt;
&gt;
CoreValve Evolut 34R TAVR system: The CoreValve Evolut 34R System is a transcatheter aortic valve implantation system comprised of the following three components:
Evolut 34R Transcatheter Aortic Valve (TAV)
&gt;
EnVeo R Delivery Catheter System (DCS) with EnVeo R InLine Sheath
&gt;
EnVeo R Loading System (LS)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With VARC II Combined Safety Endpoint Event at 30 Days</title>
          <description>VARC II composite safety endpoint includes the following components:
All-cause mortality
All stroke (disabling and non-disabling)
Life-threatening bleeding
Acute kidney injury: stage 2 or 3 (including renal replacement therapy).
Coronary artery obstruction requiring intervention.
Major vascular complication.
Valve-related dysfunction requiring repeat procedure (BAV, TAVR, or SAVR)</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" lower_limit="1.6" upper_limit="14.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Life Threatening or Disabling Bleeding</title>
        <description>Percentage of participants with life threatening or disabling bleeding - see VARC-2 definitions for classification details</description>
        <time_frame>30 days post-implantation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CoreValve Evolut 34R TAVR System</title>
            <description>Treatment of Aortic Stenosis with Medtronic CoreValve Evolut R 34R TAVR System.
&gt;
&gt;
CoreValve Evolut 34R TAVR system: The CoreValve Evolut 34R System is a transcatheter aortic valve implantation system comprised of the following three components:
Evolut 34R Transcatheter Aortic Valve (TAV)
&gt;
EnVeo R Delivery Catheter System (DCS) with EnVeo R InLine Sheath
&gt;
EnVeo R Loading System (LS)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Life Threatening or Disabling Bleeding</title>
          <description>Percentage of participants with life threatening or disabling bleeding - see VARC-2 definitions for classification details</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" lower_limit="0.2" upper_limit="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Major Vascular Complication</title>
        <description>Percentage of participants with Major vascular complication - see VARC-2 definitions for additional details</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CoreValve Evolut 34R TAVR System</title>
            <description>Treatment of Aortic Stenosis with Medtronic CoreValve Evolut R 34R TAVR System.
&gt;
&gt;
CoreValve Evolut 34R TAVR system: The CoreValve Evolut 34R System is a transcatheter aortic valve implantation system comprised of the following three components:
Evolut 34R Transcatheter Aortic Valve (TAV)
&gt;
EnVeo R Delivery Catheter System (DCS) with EnVeo R InLine Sheath
&gt;
EnVeo R Loading System (LS)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Major Vascular Complication</title>
          <description>Percentage of participants with Major vascular complication - see VARC-2 definitions for additional details</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" lower_limit="0.2" upper_limit="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Acute Kidney Injury: Stage 2 or 3</title>
        <description>Percentage of participants with Acute Kidney Injury: Stage 2 or 3 - see VARC-2 definitions for additional details</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CoreValve Evolut 34R TAVR System</title>
            <description>Treatment of Aortic Stenosis with Medtronic CoreValve Evolut R 34R TAVR System.
&gt;
&gt;
CoreValve Evolut 34R TAVR system: The CoreValve Evolut 34R System is a transcatheter aortic valve implantation system comprised of the following three components:
Evolut 34R Transcatheter Aortic Valve (TAV)
&gt;
EnVeo R Delivery Catheter System (DCS) with EnVeo R InLine Sheath
&gt;
EnVeo R Loading System (LS)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Acute Kidney Injury: Stage 2 or 3</title>
          <description>Percentage of participants with Acute Kidney Injury: Stage 2 or 3 - see VARC-2 definitions for additional details</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Coronary Artery Obstruction</title>
        <description>Percentage of participants with coronary artery obstruction - see VARC-2 definitions for additional details</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CoreValve Evolut 34R TAVR System</title>
            <description>Treatment of Aortic Stenosis with Medtronic CoreValve Evolut R 34R TAVR System.
&gt;
&gt;
CoreValve Evolut 34R TAVR system: The CoreValve Evolut 34R System is a transcatheter aortic valve implantation system comprised of the following three components:
Evolut 34R Transcatheter Aortic Valve (TAV)
&gt;
EnVeo R Delivery Catheter System (DCS) with EnVeo R InLine Sheath
&gt;
EnVeo R Loading System (LS)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Coronary Artery Obstruction</title>
          <description>Percentage of participants with coronary artery obstruction - see VARC-2 definitions for additional details</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With Valve-related Dysfunction Requiring Repeat Procedure</title>
        <description>Percentage of subjects with valve-related dysfunction requiring repeat procedure - see VARC-2 definitions for additional details</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CoreValve Evolut 34R TAVR System</title>
            <description>Treatment of Aortic Stenosis with Medtronic CoreValve Evolut R 34R TAVR System.
&gt;
&gt;
CoreValve Evolut 34R TAVR system: The CoreValve Evolut 34R System is a transcatheter aortic valve implantation system comprised of the following three components:
Evolut 34R Transcatheter Aortic Valve (TAV)
&gt;
EnVeo R Delivery Catheter System (DCS) with EnVeo R InLine Sheath
&gt;
EnVeo R Loading System (LS)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Valve-related Dysfunction Requiring Repeat Procedure</title>
          <description>Percentage of subjects with valve-related dysfunction requiring repeat procedure - see VARC-2 definitions for additional details</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With Permanent Pacemaker Implant at 30 Days</title>
        <description>Percentage of subjects with new permanent pacemaker implant at 30 days.</description>
        <time_frame>30 days</time_frame>
        <population>Subjects with pre-existing pacemaker or internal cardiac defibrillator were excluded from analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>CoreValve Evolut 34R TAVR System</title>
            <description>Treatment of Aortic Stenosis with Medtronic CoreValve Evolut R 34R TAVR System.
&gt;
&gt;
CoreValve Evolut 34R TAVR system: The CoreValve Evolut 34R System is a transcatheter aortic valve implantation system comprised of the following three components:
Evolut 34R Transcatheter Aortic Valve (TAV)
&gt;
EnVeo R Delivery Catheter System (DCS) with EnVeo R InLine Sheath
&gt;
EnVeo R Loading System (LS)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Permanent Pacemaker Implant at 30 Days</title>
          <description>Percentage of subjects with new permanent pacemaker implant at 30 days.</description>
          <population>Subjects with pre-existing pacemaker or internal cardiac defibrillator were excluded from analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.8" lower_limit="12.1" upper_limit="34.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Resheath and Recapture Success</title>
        <description>Successful resheathing is defined as Evolut R TAV (including frame) was resheathed into the capsule of the delivery cathether to the desired amount intended, as verified by fluoroscopy.
Successful recapture is defined as the entire Evolut R TAV (including frame) is resheathed into the capsule of the delivery catheter until there is no gap between the capsule and the tip, as verified by fluoroscopy.</description>
        <time_frame>Implant procedure</time_frame>
        <population>Success could only be analyzed in subjects where the resheath/recapture feature was used.</population>
        <group_list>
          <group group_id="O1">
            <title>CoreValve Evolut 34R TAVR System</title>
            <description>Treatment of Aortic Stenosis with Medtronic CoreValve Evolut R 34R TAVR System.
&gt;
&gt;
CoreValve Evolut 34R TAVR system: The CoreValve Evolut 34R System is a transcatheter aortic valve implantation system comprised of the following three components:
Evolut 34R Transcatheter Aortic Valve (TAV)
&gt;
EnVeo R Delivery Catheter System (DCS) with EnVeo R InLine Sheath
&gt;
EnVeo R Loading System (LS)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Resheath and Recapture Success</title>
          <description>Successful resheathing is defined as Evolut R TAV (including frame) was resheathed into the capsule of the delivery cathether to the desired amount intended, as verified by fluoroscopy.
Successful recapture is defined as the entire Evolut R TAV (including frame) is resheathed into the capsule of the delivery catheter until there is no gap between the capsule and the tip, as verified by fluoroscopy.</description>
          <population>Success could only be analyzed in subjects where the resheath/recapture feature was used.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hemodynamic Performance Metrics - Mean Gradient</title>
        <description>Mean gradient (mmHg) as measured by transthoracic echocardiogram and assessed by echo core laboratory</description>
        <time_frame>Baseline, 30 days, and 6 months</time_frame>
        <population>Only participants with echo could be analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>CoreValve Evolut 34R TAVR System</title>
            <description>Treatment of Aortic Stenosis with Medtronic CoreValve Evolut R 34R TAVR System.
&gt;
&gt;
CoreValve Evolut 34R TAVR system: The CoreValve Evolut 34R System is a transcatheter aortic valve implantation system comprised of the following three components:
Evolut 34R Transcatheter Aortic Valve (TAV)
&gt;
EnVeo R Delivery Catheter System (DCS) with EnVeo R InLine Sheath
&gt;
EnVeo R Loading System (LS)</description>
          </group>
        </group_list>
        <measure>
          <title>Hemodynamic Performance Metrics - Mean Gradient</title>
          <description>Mean gradient (mmHg) as measured by transthoracic echocardiogram and assessed by echo core laboratory</description>
          <population>Only participants with echo could be analyzed.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.5" spread="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 days</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.4" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hemodynamic Performance Metrics- Aortic Valve Area</title>
        <description>Aortic valve area as measured by transthoracic echocardiogram and assessed by echo core laboratory</description>
        <time_frame>Baseline, 30 Days, and 6 Months</time_frame>
        <population>Only participants with echo could be analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>CoreValve Evolut 34R TAVR System</title>
            <description>Treatment of Aortic Stenosis with Medtronic CoreValve Evolut R 34R TAVR System.
&gt;
&gt;
CoreValve Evolut 34R TAVR system: The CoreValve Evolut 34R System is a transcatheter aortic valve implantation system comprised of the following three components:
Evolut 34R Transcatheter Aortic Valve (TAV)
&gt;
EnVeo R Delivery Catheter System (DCS) with EnVeo R InLine Sheath
&gt;
EnVeo R Loading System (LS)</description>
          </group>
        </group_list>
        <measure>
          <title>Hemodynamic Performance Metrics- Aortic Valve Area</title>
          <description>Aortic valve area as measured by transthoracic echocardiogram and assessed by echo core laboratory</description>
          <population>Only participants with echo could be analyzed.</population>
          <units>cm2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 days</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hemodynamic Performance Metrics - Total Prosthetic Regurgitation Graded as None/Trace</title>
        <description>Total prosthetic regurgitation (none/trace) as measured by transthoracic echocardiogram and assessed by echo core laboratory</description>
        <time_frame>30 days and 6 months</time_frame>
        <population>Only participants with echo could be analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>CoreValve Evolut 34R TAVR System</title>
            <description>Treatment of Aortic Stenosis with Medtronic CoreValve Evolut R 34R TAVR System.
&gt;
&gt;
CoreValve Evolut 34R TAVR system: The CoreValve Evolut 34R System is a transcatheter aortic valve implantation system comprised of the following three components:
Evolut 34R Transcatheter Aortic Valve (TAV)
&gt;
EnVeo R Delivery Catheter System (DCS) with EnVeo R InLine Sheath
&gt;
EnVeo R Loading System (LS)</description>
          </group>
        </group_list>
        <measure>
          <title>Hemodynamic Performance Metrics - Total Prosthetic Regurgitation Graded as None/Trace</title>
          <description>Total prosthetic regurgitation (none/trace) as measured by transthoracic echocardiogram and assessed by echo core laboratory</description>
          <population>Only participants with echo could be analyzed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>30 days</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>EVOLUTR 34R</title>
          <description>Participants implanted with EVOLUTR 34R device</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Coagulopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Myocardial Infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Atrioventricular Block</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Atrioventricular Block Complete</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Atrioventricular Block First Degree</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Bundle Branch Block Left</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Cardiac Arrest</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Cardiac Failure Acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Cardiac Failure Congestive</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Cardio-Respiratory Arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Cardiogenic Shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Conduction Disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Nodal Rhythm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pulseless Electrical Activity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Supraventricular Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Ventricular Tachycardia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision Blurred</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Rectal Haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Device Embolisation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Generalised Oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Viral Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arterial Injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Compression Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hip Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Lung Neoplasm Malignant</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular Accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hypoxic-Ischaemic Encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Transient Ischaemic Attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional State</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Glomerulonephritis Membranous</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Urinary Retention</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Respiratory Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Bronchiectasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pulmonary Oedema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Femoral Artery Dissection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Peripheral Ischaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Atrioventricular Block First Degree</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Bundle Branch Block Left</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Extrasystoles</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Sinus Bradycardia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Myocardial Necrosis Marker Increased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hypervolaemia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Urinary Retention</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sara Saul</name_or_title>
      <organization>Medtronic</organization>
      <phone>763-526-1965</phone>
      <email>sara.m.saul@medtronic.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

